Androgen deprivation therapy for prostate cancer is associated with significant metabolic and cardiovascular adverse effects that require clinical awareness and management.
ADT-associated CV risks warrant monitoring in prostate cancer; Level 5 data leave optimal risk-benefit balance open.
ver the past decade, use of androgen deprivation therapy (ADT) to treat prostate cancer has risen seven-fold, from 9.8% of patients in 1989-1992 to 74.6% in 1991-2001 (1). ADT is used as neoadjuvant and adjuvant treatment with radiation therapy (RT), to treat recurrence following primary treatment with surgery or RT, or when the cancer is in an advanced stage at diagnosis. While ADT has demonstrated survival benefits, it also is associated with increases in metabolic and cardiovascular risks. Men receiving ADT have been shown to develop dyslipidemia, decreased arterial compliance, increased insulin resistance, weight gain with increased visceral fat deposition, decreased bone mineral density, decreased libido and erectile dysfunction, fatigue, cognitive changes and depression (1-12) O
No takes yet. Share an insight, caveat, or question.
Maliski et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: